Advancell raised an oversubscribed $315 million Series D to accelerate development of its L-212 prostate-specific membrane antigen-targeted radioligand, ADVC-001, and to expand isotope supply and manufacturing capacity. The capital supports late-stage clinical work in metastatic castration-resistant prostate cancer, reflecting how radiopharma is increasingly treating supply chain buildout as part of the drug development plan. The round also signals continued investor appetite for near-commercial platform assets where manufacturing constraints can be addressed upfront, rather than deferred. Advancell’s funding package includes both clinical and industrial scale-up commitments, aiming to reduce bottlenecks that have slowed isotope-dependent therapeutics. Separately, Chai Discovery’s $400 million Series C financing boosted the company’s valuation to $3.8 billion, reflecting market confidence in AI systems used by major pharma for de novo molecular generation and improved antibody design performance.